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The cholesterol-dependent cytolysins (CDCs) punch
holes in target cell membranes through a highly regu-
lated process. Streptococcus mitis lectinolysin (LLY)
exhibits another layer of regulation with a lectin
domain that enhances the pore-forming activity of
the toxin. We have determined the crystal structures
of the lectin domain by itself and in complex with
various glycans that reveal the molecular basis for
the Lewis antigen specificity of LLY. A small-angle
X-ray scattering study of intact LLY reveals the mole-
cule is flat and elongated with the lectin domain
oriented so that the Lewis antigen-binding site is
exposed. We suggest that the lectin domain en-
hances the pore-forming activity of LLY by concen-
trating toxin molecules at fucose-rich sites on
membranes, thus promoting the formation of pre-
pore oligomers on the surface of susceptible cells.
INTRODUCTION
The cholesterol-dependent cytolysins (CDCs) are one of the
most widely distributed toxins known, having been identified in
five different genera of Gram-positive bacteria (Tweten, 2005).
The CDCs exhibit a number of unique features among pore-
forming toxins, including an absolute dependence on the pres-
ence of cholesterol-rich membranes for their activity and the
formation of oligomeric transmembrane pores greater than
150 A˚ in diameter. There are more than 20 members of the
CDC family identified so far, and there exists a high degree of
sequence homology (40%–70%), suggesting they all have
similar activities and three-dimensional structures. The latter
has been confirmed with crystal structures determined for per-
fringolysin O (PFO) (Rossjohn et al., 1997, 2007), intermedilysin
(ILY) (Polekhina et al., 2005), anthrolysin O (ALO) (Bourdeau
et al., 2009), and suilysin (SLY) (Xu et al., 2010). Functional
studies have revealed that CDCs undergo a highly regulated
stepwise process in assembling as a large membrane pore con-248 Structure 20, 248–258, February 8, 2012 ª2012 Elsevier Ltd All rsisting of more than 30monomers (Tweten, 2005). Not only is the
conversion fromwater-solublemonomer to pore highly complex,
but it is also essential that the pore does not form prematurely,
otherwise the target cell will not be successfully breached.
Streptococcus mitis is a member of the viridans streptococci
and usually found in the normal flora of the mouth and throat.
Together with other members of the viridans family, it can cause
a number of diseases such as infective endocarditis, bacteremia,
and septicemia (Hall and Baddour, 2002; Huang et al., 2002;
Gowda et al., 2003; Kennedy et al., 2004). S. mitis was a causa-
tive agent for a large outbreak of toxic shock-like syndrome in
China (Lu et al., 2003) and has also been associated with Kawa-
saki disease (Ohkuni et al., 1997). A possible pathogenesis factor
for these diseases is a protein secreted by the bacterium that
was isolated from serum of patients who suffered fromKawasaki
disease. The protein was suggested to have the ability to aggre-
gate human platelets on the basis of an observed change in light-
scattering properties and, therefore, was called platelet aggre-
gation factor (PAF). Ohkuni et al. (2006) showed that antibody
titers to a PAF-derived peptide were significantly elevated in
children with Kawasaki disease, a disease often associated
with platelet aggregation and coronary artery thrombosis. Amino
acid sequence analysis of PAF (Sm-hPAF-NM-65, GenBank
accession number AB051299.1) revealed that the DNA-derived
sequencewas related to ILY, a CDC produced byStreptococcus
intermedicus (Nagamune et al., 2000).
Farrand et al. (2008) performed an extensive study of PAF and
found that it shared a number of characteristics typical of CDCs.
Of note, their studies showed that PAF did not appear to aggre-
gate platelets. The changes in light-scattering properties of the
platelets observed by Ohkuni et al. (1997) were apparently due
to changes of the shape of the platelets induced by the formation
of pores, not their aggregation. A special feature of the toxin is the
presence of an additional amino-terminal domain of 162 amino
acids that is not present in other CDCs. This domain was found
to share significant sequence identity with proteins that bind
glycans-containing fucosylated structures. These observations
led Farrand et al. to rename PAF as lectinolysin (LLY).
Farrand et al. (2008) showed that the presence of the lectin
domain (LLYlec) enhanced the formation of pores on platelets
compared to LLYCDC (where LLYCDC is a mutant molecule thatights reserved
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Lectinolysin-Lewis Antigen Complexeslacks the lectin domain), presumably because the domain inter-
acted with one or more glycans on the cell surface of platelets.
Glycan array analysis revealed that LLYlec had a preference for
binding to the difucosylated glycans Lewis y (Ley) antigen and
Lewis b (Leb) antigen. These Lewis carbohydrate antigens are
blood group antigens, which are classified as either type 1 or
type 2 antigens. Leb is one of the type 1 antigens that are impor-
tant histo-blood group antigens, whereas Ley belongs to type 2
and is only expressed in a few cell types (Yuriev et al., 2005).
The latter has been associated with tumor cells due to elevated
expression levels in a number of cancerous cells and, as such, is
a promising target for cancer therapy (Yuriev et al., 2005).
Opportunistic bacteria often utilize proteins bearing lectin
domains to help target host cell glycoconjugates for recognition
(Imberty and Varrot, 2008). However, LLY is the only reported
CDC to date that utilizes this strategy as a part of its host cell
recognition mechanism. Here we describe the crystal structure
of LLYlec complexed to glycerol and three saccharides: fucose
and the two difucosylated glycans Leb and Ley. These structures
show that LLYlec adopts a relatively rare fold in the lectin super-
family and reveals the molecular basis for the lectin’s glycan
specificity. Small-angle X-ray scattering (SAXS) was used to
determine how the lectin domain interacts with the rest of the
toxin molecule. These studies show that the fucose-binding
site is fully accessible to the environment, in contradiction to
earlier reports (Farrand et al., 2008), and thus already primed
for interaction with host cell glycoreceptors.
RESULTS
Structure of LLYlec
The final structure of LLYlec consists of residues 44 to 185
(Table 1), which adopt an eight-stranded b sandwich fold
made up by a five-stranded antiparallel b sheet (b1, b2, b4, b5,
and b7) on one side and a three-stranded antiparallel b sheet
(b3, b6, and b8) on the other side (Figure 1). (A cartoon diagram
of a model of full-length LLY indicating where LLYlec is located in
comparison with the rest of the molecule is shown in Figure S1,
available online.) b strands 1 and 2 are separated by a long loop
(residues 59 to 91) containing two short a helices (a1 and a2), and
another short a helix (a3) is positioned between b strands 3
and 4. There are numerous salt bridges in the structure (Glu 45
to Arg 182, Glu 47 to Arg 182, Asp 75 to His 80, Asp 90 to Lys
169, Asp 97 to Arg 160, Glu 151 to Lys 106, Glu 149 to Lys
108, Asp 114 to Arg 112, Asp 125 to Arg 138, Asp 142 to His
140, Glu 165 to Lys 163, and Glu 179 to Lys 108). An intrasheet
salt bridge from Asp 97 to Arg 160 forms a link between the N
terminus of b strand 2 with the C terminus of b strand 7.
A calcium ion is positioned between backbone carbonyls of
Arg 68, Asp 73, Ser 82, and Ala 176 and side-chain residues of
Asp 71, Ser 82, and Glu 177. The position of this ion is conserved
in other fucolectins domains (Bianchet et al., 2002; Boraston
et al., 2006) and in a number of carbohydrate-binding module
(CBM) families (Boraston et al., 2004). It plays an important role
in the interaction of many lectins with their target ligands, either
by maintaining the binding site in the correct conformation or
through direct coordination with the carbohydrate itself.
The electron density map revealed that one glycerol molecule
was embedded in a hydrophobic pocket created by residuesStructure 20, 24Tyr 62, Tyr 78, Phe 88, and Val 117 and the basic residues His
85, Arg 112, and Arg 120 (Figures 1 and 2A). The glycerol mole-
cule forms hydrogen bonds with His 85, Arg 112, and Arg 120.
The equivalent residues are conserved in other lectin domains
(Bianchet et al., 2002; Boraston et al., 2006). In addition to the
direct hydrogen bonds, the glycerol molecule also takes part in
66 van der Waals interactions with various residues in the
pocket. More than two thirds (69% or 151 A˚2) of the surface of
the glycerol molecule is buried in the complex. The origin of
this glycerol molecule was the cryosolution that was used to
protect the crystal from radiation damage.
Glycan Interactions with LLYlec
LLYlec-Fucose Complex
The electron density for the a-L-fucose waswell defined, located
in the same pocket as the glycerol molecule described above,
with an occupancy of 0.6 (Figure 2B). The fucose molecule is
directly bound to the NE atom of His 85 and the NH1 and NH2
atoms of Arg 112 and Arg 120. Arg 112 is an important residue
for binding of sugars by LLYlec as it was shown by Farrand
et al. (2008) that the binding activity of LLYlec was eliminated
when this residue was mutated to an alanine residue. There is
one water-mediated hydrogen bond between fucose and Gly
115. The fucosemolecule also takes part in hydrophobic interac-
tions with Tyr 62, Tyr 78, Phe 88, and Val 117. In total, there are
94 van der Waals interactions between fucose and protein. The
formation of the complex results in a buried surface area of
more than two thirds (66% or 192 A˚2) of the fucose molecule.
The structure of the monomer is identical to that found in the
LLYlec – glycerol complex, comprising the same number of resi-
dues and no significant changes in temperature factors.
LLYlec-Lewisy Antigen Complex
The overall protein structure of the Ley complex is identical to the
LLYlec structures described earlier, with the same number of
residues and no significant changes in temperature factors.
The electron density for the Ley antigen Fuc(a1-2)Gal(b1-4)
[Fuc(a1-3)]GlcNAc was readily modeled in the initial electron
density maps. Henceforth, we refer to Fuc(a1-2) as the fucose 1
moiety and Fuc(a1-3) as the fucose 2 moiety. The Ley antigen is
fully occupied in its binding site (Figure 2C). Fucose 1 of the Ley
antigen was located in the same place and binds in the same
manner as the fucose molecule seen in the structure of the
LLYlec – fucose complex. In addition, there are eight water mole-
cules that are involved in water-mediated hydrogen bonds
between ligand and protein (including interactions with the Ni
ion; see Experimental Procedures). Two of these water mole-
cules mediate interactions between one fucose moiety and Gly
115 and Tyr 62, and another mediates an interaction between
the galactose moiety and Asp 114. The remaining water mole-
cules mediate interactions between the fucose 2 and Asp 77,
Gly 79, and the Ni ion. In contrast, the GlcNAc moiety is not
involved in any direct or indirect hydrogen bonds. In total, there
are 19 van der Waals interactions between the ligand and the
protein. Of these interactions, 15 are with fucose 1, 1 with galac-
tose, 1with GlcNAc, and 2with fucose 2. About one third (38%or
283 A˚2) of the Ley antigen is buried because of the formation of
the complex. Fucose 1, which is hydrogen bonded to residues
His 85, Arg 112, and Arg 120, is embedded most in the shallow
binding pocket. Galactose and fucose 2 are located further8–258, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 249
Table 1. Crystallographic Data Processing and Refinement Statistics
Variable LLYlec LLYlec-Fucose LLYlec-Ley LLYlec-Leb
Data collection
Wavelength (A˚) 0.95 1.54 1.54 1.54
Temperature (K) 100 100 100 100
Maximum resolution (A˚) 1.9 1.9 2.0 2.2
Space group P43212 P43212 P43212 P43212
Unit cell dimensions (A˚) 67.2, 67.2, 98.4 67.0, 67.0, 97.8 67.1, 67.1, 98.6 67.0, 67.0, 97.7
No. of observations 268,267 154,987 184,195 134,919
No. of unique reflections 16,856 18,008 15,622 11,851
Redundancy 15.9 8.6 11.8 11.4
Data completeness (%) 91.5 (72.3) 98.6 (87.7) 99.8 (99.8) 99.7 (99.7)
I/sI 28.0 (4.1) 9.6 (4.0) 9.7 (4.1) 14.0 (6.9)
Rmerge (%)
a 9.1 (55.6) 12.4 (42.9) 14.3 (49.2) 9.6 (27.0)
Refinement
Nonhydrogen atoms
Protein 1,112 1,114 1,115 1,100
Water 164 144 121 135
Ni2+ 1 1 1 1
Ca2+ 1 1 1 1
Ligands 6 11 46 46
Resolution (A˚) 1.9 1.9 2.0 2.2
Rwork (%)
b 17.5 19.9 19.3 20.2
Rfree (%)
c 20.6 24.7 23.4 23.7
Rms deviations from ideal geometry
Bond lengths (A˚) 0.015 0.017 0.018 0.017
Bond angles (degrees) 1.5 1.4 1.6 1.5
Bonded Bs 1.7 1.7 2.0 1.6
Mean B (A˚2)
Main chain 23.5 22.3 20.5 17.8
Side chain 25.7 23.7 22.2 19.6
Water 34.5 30.1 27.3 25.5
Residues in most favored regions
of the Ramachandran plot (%)
89.1 85.4 86.0 85.9
Residues in the disallowed regions
of the Ramachandran plot (%)
0 0 0 0
The values in parentheses are for the highest resolution bin (approximately 0.1 A˚ width).
aRmerge = ShklSijIi - < I > j/j < I > j, where Ii is the intensity for the ith measurement of a symmetry-related reflection with indices h,k,l.
bRwork = SkFobsj – jFcalck/SjFobsj, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively.
cRfree was calculated with 5% of the diffraction data that were selected randomly and not used throughout refinement.
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Lectinolysin-Lewis Antigen Complexesaway from the pocket and increase the complementarity by
forming water-mediated hydrogen bonds.
We wondered whether the Ley antigen could also bind into the
fucose 1-binding site (described earlier) through the fucose 2
moiety instead. However, model building showed that, with
fucose 2 deep in the pocket, the galactose moiety would likely
clash with Tyr 62 and the fucose 1 moiety would have no interac-
tions with the protein. Thus, fucose with an a1-2 linkage may be
responsible for determining the specificity of LLY for Ley and Leb
over Lex and Lea.
LLYlec-Lewisb Antigen Complex
The model of the Leb complex consists of residues 44 to 184.
The electron density for the Leb antigen (Fuc(a1-2)Gal(b1-3)250 Structure 20, 248–258, February 8, 2012 ª2012 Elsevier Ltd All r[Fuc(a1-3)]GlcNac) was clearly visible and located in the same
binding pocket as found for the Ley antigen (Figure 2D). The
site is fully occupied by the ligand in the crystal. The Ley and
Leb antigens of the LLYlec complex structures superimpose
well and there are no structural differences in the binding site
of LLYlec. The only structural difference between Ley antigen
and the Leb antigen is the opposing projections of the N-acetyl
and CH2OH groups of the N-acetylglucosamine (GlcNAc). The
hydrogen bonding interactions for Leb antigen are the same as
for Ley antigen with the exception of the O atom in the N-acetyl
group that forms a hydrogen bond to Tyr 62. Overall, there are
23 van der Waals interactions. The protein forms 15 van der
Waals contacts with fucose 1, 1 with galactose, 3 with GlcNacights reserved
Figure 1. Structure of LLYlec
(See also Figure S1, which shows how LLYlec is oriented with respect to the
rest of the toxin molecule.) The structure is represented in colors, from the N
terminus in magenta to the C terminus in red. Glycerol is shown as ball and
stick, the calcium ion is shown as a red sphere, and the Ni ion is shown as
a magenta sphere. Secondary structural elements and CDR loops are labeled
as described in the text. This and all following structural figures were drawn
with PyMol (Delano, 2002).
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Lectinolysin-Lewis Antigen Complexesand 4 with fucose 2. The complementarity of Leb to the protein is
enhanced by water-mediated hydrogen bonds between galac-
tose and fucose 2 with the protein, as was observed in the Ley
complex structure. More than one third (40% or 292 A˚2) of the
total surface area of the Leb antigen and 221 A˚2 of the total
surface area of the protein is buried due to the formation of the
complex.
LLYlec Dimers
All four crystal structures revealed a head-to-head dimer, gener-
ated by crystallographic symmetry (Figure 3). Superposition of all
four complex structures showed that the structures are almost
identical with a root-mean-square (rms) deviation of the alpha
carbon atoms of 0.15 A˚ (Figure 3). The total surface area of
the dimer interfaces is approximately 318 A˚2 per monomer.
The residues of the monomers that are involved in dimer
contacts are all located on a long loop opposite the b sandwich
and on b strand 1. There are four direct hydrogen bonds—Gln
54A (OE1) to Gln 54B (NE2), Gln 54B (OE1) to Gln 54A (NE2),
Gly 63A (O) to Arg 68B (NH1), and Gly 63B (O) to Arg 68A
(NH1)—as well as four water-mediated hydrogen bonds at the
interface. The recombinant forms of LLYlec and full-length LLYStructure 20, 24used in this study exist as mixtures of monomers and dimers in
solution but were readily dissociated to monomers in the pres-
ence of DTT (data not shown). Thus, the LLYlec dimers seen in
the crystal do not appear relevant to the intact toxin in its
secreted state, although they may bear some relevance to how
the toxin molecules pack in the prepore/pore forms of the toxin.
Comparison with Other Lectin Domains
A search for similar structures to LLYlec in the Protein Data Bank
using the DALI server (Holm and Sander, 1993) revealed two
structures with scores greater than 20: Anguilla anguilla (eel)
agglutinin (AAA) and the CBM family 98 glycoside hydrolase
of Streptococcus pneumonia (SpX-1). LLYlec shares 33%
sequence identity with AAA and 47% sequence identity with
SpX-1. The crystal structure of the AAA fucolectin domain was
shown to be a novel fold within the lectin family (Bianchet
et al., 2002). Superposition of this structure and LLYlec shows
similarities in their cores. The domains superimpose with rms
deviations of the alpha carbon atoms of 1.5 A˚ (Figure 4A). In
contrast to LLYlec, the fucolectin domain of AAA forms a tight
trimer in the crystal. The AAA domain has additional residues
at the N terminus and the C terminus, which form an antiparallel
two-stranded b sheet. The loop between strands 5 and 6 in
LLYlec has moved away from the core structure. Like the AAA
domain, LLYlec contains five loops that form the boundary for
the carbohydrate-binding site and connect the two b sheets at
one end of the barrel. These loops were named complemen-
tarity-determining regions (CDRs) by Bianchet et al. (2002) in
analogy with the nomenclature for immunoglobulins. In immuno-
globulins, the CDRs are hypervariable regions and serve to
recognize and bind specifically to antigens. The CDRs in LLYlec
are CDR1 (Thr 60 to Gly 64), CDR2 (Val 74 to Val 83), CDR3
(Thr 86 to Asn 91), CDR4 (Arg 112 to Phe 124), and CDR5 (Leu
167 to Pro 172). CDR1 in AAA is five residues longer and not
as tightly packed as in LLYlec. This loop creates a deeper pocket
for the fucose compared to LLYlec. CDR4 and CDR5 are one
residue longer in LLYlec compared to the AAA domain. As in
AAA, CDR5 is the loop farthest away from the binding site. The
loop between strands 4 and 5 is four residues longer than in
LLY. In the AAA domain, there is an additional helix between
b strands 1 and 2 (definition according to LLYlec). Among
different fucolectins of Anguilla japonica (Japanese eel), the
CDR loops around the binding site contain high sequence vari-
ability, suggesting that these loops modulate the fine specificity
of lectins for different host cell receptors.
Fucose is positioned in the same pocket in AAA, as observed
in the LLYlec structures, and makes contact with the conserved
residues His 52, Arg 79, and Arg 86 (His 85, Arg 112, and
Arg 120 in LLYlec). However, AAA lacks affinity for Ley antigens
or any other antigens belonging to type 2, but it can bind the
fucosylated terminals of H and Lewis (a) blood groups. Modeling
by Bianchet et al. (2002) suggested that the CDR1 loop of AAA
must undergo a large structural disruption for binding of type 2
antigens to occur, but the loop is very rigid with low B factors
and hence unlikely to be able to move. A Ca2+ ion is located in
the same position in the AAA and LLYlec structures. It was found
that the addition of calcium to AAA and related proteins (Saito
et al., 1997) increased the affinity for carbohydrates despite
the fact that the Ca2+ ion was not directly located near the8–258, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 251
Figure 2. Close-up Stereo Views of the
Ligand Binding Pocket of LLYlec
LLYlec is complexed to (A) glycerol, (B) a-L-fucose,
(C) Ley antigen, and (D) Leb antigen. Residues that
create the binding pocket are shown as blue and
magenta sticks and the ligands as yellow sticks.
Water molecules are shown as green spheres, and
hydrogen bonds by dashed lines.
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Lectinolysin-Lewis Antigen Complexesresidues involved in sugar binding. Thus, the ion is considered to
play an important structural role in carbohydrate recognition.
The structure of SpX-1 (Boraston et al., 2006) was determined
uncomplexed (PDB code 2J1R) and in complex with a number of
carbohydrates including fucose (PDB code 2J1S), the type 2
H-trisaccharide (PDB code 2J1V), the blood group A-tetrasac-
charide analog (PDB code 2J1U), and the Ley antigen (PDB
code 2J1T). SpX-1 forms a head-to-tail dimer in the asymmetric
unit in contrast with the head-to-head dimer found for LLYlec. It is
not clear whether the SpX-1 dimer has any physiological rele-252 Structure 20, 248–258, February 8, 2012 ª2012 Elsevier Ltd All rights reservedvance. Superposition of the alpha car-
bons of the LLYlec on to SpX-1 gives rms
deviations of 0.6 A˚ (Figure 4B). Thus, the
structures superimpose closely, but there
are differences in the loop regions. The
loop connecting b strands 4 and 5 is
one residue longer in SpX-1 and points
outward in SpX-1 rather than upward
(because of crystal contacts). CDR4 is
one amino acid longer in LLYlec
compared to SpX-1. The tips of CDR3
and CDR5 are slightly shifted outward
compared to the LLYlec structure as the
residues form crystal contacts to the
other monomer of the dimer.
Fucose, in complex with SpX-1, as well
as in the complex structure of SpX-1 and
Ley antigen, is located in the same pocket
and makes the same contacts as those
seen for fucose in the LLYlec complex
structure. Again, a Ca2+ ion is positioned
in SpX-1 in the same binding pocket as
that found in the LLYlec and AAA struc-
tures. Analysis of the complex structure
of SpX-1 and Ley antigen shows that
the Gal-GlcNAc-Fuc groups of the Ley
antigen have shifted approximately
2.9 A˚ compared to the same groups in
the LLYlec-LeY complex (Figure 4C). This
is due to differences in the amino acid
sequence of the CDR2 and CDR4 loops
and crystal contacts in the complex
structure of SpX-1 and Ley antigen
compared to LLYlec. It is not surprising
that the water network around the Ley
antigen is strikingly different between
LLYlec and SpX-1. The water-mediated
hydrogen bonds between fucose 2 and
protein and between galactose and Asp114 pulls the Ley antigen further into the binding pocket of
LLYlec compared to SpX-1.
LLYlec Recognition of Lewis Antigens and Comparison
with Other Lewis Antigen-Binding Proteins
Lea of type 1 and Lex of type 2 structures contain one fucose
unit, whereas Leb of type 1 and Ley of type 2 have two fucose
units each. The difference between type 1 and 2 antigens is
the core disaccharide linkage with an opposing projection of
the N-acetyl and –CH2OH groups of the N-acetylglucosamine
Figure 3. Superposition of the Dimers of LLYlec
The dimers are created by crystallographic symmetry. The dimers of LLYlec,
LLYlec-fucose, LLYlec-Ley, and LLYlec-Leb are shown in red, yellow, blue, and
green, respectively. The Ca2+ ion is shown in blue.
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Lectinolysin-Lewis Antigen Complexesmonosaccharide. The overall Lewis determinants maintain the
same conformation in both free and bound states (Yuriev et al.,
2005). The rings of the two constant moieties, fucose and galac-
tose, are usually tightly stacked in a rigid conformation. The addi-
tion of the fucose residue to the GlcNAc residue (forming Ley
from type 2 and Leb from type 1 chains) does not cause a signif-
icant conformational change. To date, only a few structures
complexed to Lewis antigens have been described. Apart from
SpX-1 (described earlier), lectin structures complexed with Ley
and Leb antigens have been reported for the legume lectin
from Griffonia simplifolia (Delbaere et al., 1993) (PDB codes:
1LED and 1GSL). The structures of both Ley and Leb antigen
as observed bound to the legume lectins and to LLYlec are very
similar despite the binding pockets adopting very different
shapes and nonsuperimposable CDR loops (Figure 5A).
The structure of a humanized antibody with high specificity
toward type 2 antigens (hu3S193) has been reported as a
complex with Ley (Ramsland et al., 2004; Farrugia et al., 2009).
The Ley antigen was positioned in a pocket between heavy
and light chains of the antibody, and each of the hexose rings
was involved in hydrogen bonding (Figure 5B). The structure
also revealed an extensive network of water molecules, which
was thought to play a role in recognition of the Ley antigen.Structure 20, 24Specificity of Ley over Leb antigen was determined by chemical
restraints. The N-acetyl oxygen atoms of Ley are bound by
a conserved hydrogen bond to the main-chain amide group of
residue Tyr 33H. Additionally, the side chain of Tyr 33H was
stacked against the hexose ring of GlcNAc and parts of the
adjoining Gal moiety. These interactions are not possible with
type 1 Lewis structures, as the N-acetyl groups of the N-acetyl-
glucosamine would be forced away from the specific pocket
formed by Tyr 33H. The specificity for type 2 antigenswas further
enhanced in the hu3S193 complex by solvent-mediated
hydrogen bonding of the N-acetyl and CH2OH groups of
GlcNAc. Comparison of the Ley antigens of the LLYLec structure
with the Ley antibody structure reveal that the Lewis carbohy-
drate determinants are similar but that the shape of the binding
pocket formed by the heavy and light chains and the amino acids
involved in binding to Ley of the antibody are very different
compared to the CDR loops of the lectin structures (Figure 5B).
Fucose 1 of Ley in the LLYlec complex structure is the anchoring
glycan (the moiety that is deepest in the binding pocket),
whereas, in the antibody complex, fucose 2 is embedded deep-
est in the pocket.
LLYlec Has an Integrin-Binding RGD Motif
LLYlec has an integrin-binding Arg-Gly-Asp (RGD) motif located
on the loop between b strands 5 and 6 (Figure 1), and Arg 112
of the motif has been shown to be critical for Lewis antigen
binding (Farrand et al., 2008). The same motif, located in the
same position, is found in AAA (Bianchet et al., 2002). We were
interested in whether the motif could be functional as an integ-
rin-binding site. First, we superimposed the RGD loop of LLYlec
on to the structure of an RGD pentapeptide bound to the integrin
aVb3 (PDB id: 1L5G; Xiong et al., 2002). The superposition
resulted in clashes between LLYlec and the integrin, suggesting
that, if they do bind, then conformational changes are required
of one or both binding partners. There is evidence in the literature
that the integrin can undergo large quaternary comformational
changes on binding RGD-containing proteins (Lee et al., 1995;
Xiong et al., 2002; Takagi et al., 2003).
Small-Angle X-Ray Scattering of Intact LLY
To experimentally determine the position of the LLYlec domain
with respect to the LLYCDC, we performed SAXS analysis ofFigure 4. Structural Similarities of LLYlec to Other
Proteins
(A) Superposition of the LLYlec domain (in blue) on to the
structure of the fucolection of AAA (in red). Both structures
are complexed with fucose. The Ca2+ atom, which is
located in the same position in both structures, is shown in
green. The CDR loops that are different in AAA, compared
to the LLYLec domain, are shown in yellow.
(B) Superposition of the fucose complex structures of
LLYlec domain (in blue) and the fucolectin module of SpX-1
(in orange).
(C) Superposition of the Ley antigen complex structures of
LLYlec domain (in blue) and the fucolectin module of SpX-1
(orange).
8–258, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 253
Figure 5. Protein Recognition of Lewis Antigens
All superpositions are based on the Lewis antigen, and LLYlec is shown in
orange.
(A) Griffonia simplifolia legume lectin (PDB code: 1LED) is shown in blue with
Lewis b antigens superimposed.
(B) Monoclonal antibody hu3S193 (PDB code: 1SK3) heavy and light chains
are shown in different shades of blue, with Lewis y antigens superimposed.
Structure
Lectinolysin-Lewis Antigen Complexesthe full-length toxin. (More details are provided in the Supple-
mental Information, including Figure S2.) We calculated an ab
initio shape envelope of LLY from the P(r) distribution using
dummyatommodeling (FrankeandSvergun, 2009). Theenvelope
was elongated and relatively flat but with a slight bend. Computa-
tional docking of available CDC crystallographic models, repre-
senting LLYCDC, into the shape envelope suggested that the
bend was best described by the structure of ALO (Bourdeau
et al., 2009). LLYCDC and ALO share 29.6% pairwise sequence
identity. These studies also revealed the presence of contiguous
unfitted electron density in the plane of the LLYCDC adjacent to
its N terminus (Figure 6A). Therefore, a homology model of the
LLYCDC was generated with the ALO coordinates, and the SAXS
data were used to establish the optimal relative positioning of
the LLYlec domain. Simulated annealing and random search
methods identified similar LLYlec positions that were consistent
with the ab initio shape envelope (Figures 6A and 6B).254 Structure 20, 248–258, February 8, 2012 ª2012 Elsevier Ltd All rOverall, the SAXS analysis indicates that (1) the LLYCDC region
is flat and elongated in solution, as seen in the crystal structures
of other CDCs; (2) domain 4 is angled with respect to domains
1–3, and the angle is similar to that in ALO; and (3) the LLYlec
domain packs its N and C termini against the N terminus of the
LLYCDC, thus exposing the Lewis antigen-binding site.
DISCUSSION
To date, the only CDC described to have an N-terminal lectin
domain has been LLY. The structures presented here reveal
that LLYlec has a F-type lectin fold, first described in the crystal
structure of AAA in 2002 (Bianchet et al., 2002). Comparison of
the two structures reveals that the core structures are very similar
but that there are differences in the CDR loops. These loops have
been shown to exhibit a high degree of sequence and conforma-
tional variability among the different AAAs so they can recognize
different glycans. One of the loops in the AAA domain is longer
than in the LLYlec domain and was very rigid. Such features are
presumably the reason why AAA lacks affinity for type 2 antigens
and prefers to form complexes with type 1 antigens. Structural
comparison of LLYlec with SpX-1, the fucose-binding module
of the putative Streptococcus pneumoniae family 98 glycoside
hydrolase, revealed smaller differences in the loops, and, in
contrast to AAA, the SpX-1 domain shows affinity for a number
of oligosaccharides. The complex structure of Ley bound to
SpX-1 shows that the Lewis antigen is located in the same
pocket as in LLYlec, but a shift was observed because of differ-
ences in residues of the binding pocket compared to LLYlec
and the presence of crystal contacts in SpX-1.
The structures of the complexes with fucose and the blood
group antigens Ley and Leb demonstrate that the main binding
determinant is one of the fucose rings—fucose 1, which interacts
with the three residues, His 85, Arg 112, and Arg 120—with the
other fucose ring (fucose 2) interacting with the protein through
mainly water-mediated interactions. The equivalent residues
are highly conserved in other lectin domains. Arg 112 is part of
an RGD motif, which is found in cell adhesion proteins (Piersch-
bacher et al., 1985) and is a typical integrin-binding motif (Xiong
et al., 2002). The presence of the motif in LLYlec suggests that it
may have integrin-binding properties. However, integrin binding
of the LLYlec domain has not been reported, and our analysis
suggests that the LLYlec domain is unlikely to form a complex
with integrins, unless large conformational changes take place
in both the integrin and the lectin. The other sugar rings of the
Ley and Leb antigens make relatively few direct contacts with
protein residues.
The SAXS analysis of the full-length toxin suggests that
LLYCDC domains 1–4 are in an extended planar arrangement in
solution, as seen in crystal structures for other CDCs,with a slight
bend between domains 3 and 4, similar in amplitude to that in
ALO (Bourdeau et al., 2009). The SAXS modeling predicts that
the C terminus of the LLYlec domain is close to the N terminus
of domain 1 of the LLYCDC region. The LLYlec domain lies in the
plane of the LLYCDC, with the Lewis antigen- binding site distal
from the CDC. In this arrangement, the Lewis antigen-binding
site would be exposed on the outer surface of the pore based
on models of the pneumolysin pore generated by electron
microscopy (Gilbert et al., 1999; Tilley et al., 2005).ights reserved
Figure 6. Comparison of the Ab Initio Shape Envelope with Computationally Docked and SAXS-Derived LLY Models
Each panel shows orthogonal views of the fits. The blue spheres represent missing C-terminal residues and loops between secondary structural elements,
including the linker peptide between the lectin domain and the rest of the toxin molecule, which were missing in the ALO structure that was used in the modeling.
See also Figure S2 for the SAXS data.
(A) Rigid-body refinement of the position of the LLYlec domain with BUNCH (Petoukhov et al., 2005) generated an ensemble of models that were in good
agreement with the experimental scattering profile. In all thesemodels, the position of the LLYlec domain correspondedwell to the unoccupied density proximal to
the N terminus of the LLYCDC domains in the shape envelope. The BUNCH model closest to the average position is shown.
(B) As an alternatemethod of identifying likely LLYlec domain positions, a large pool ofmodels with randomized LLYlec and LLYCDC orientations, constrained by the
intervening linker sequence, were generated and interrogated with the EOM (Bernado´ et al., 2007). The individual EOM models in the pool with theoretical
scattering profiles that best matched the experimental curve were identified. The EOM model closest to the average position is shown.
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Lectinolysin-Lewis Antigen ComplexesFarrand et al. (2008) showed that the binding site for saccha-
rides is occluded in the full-length toxin but is revealed on
binding of the toxin to the cell surface. However, the SAXSmodel
shows that the Lewis antigen-binding site is exposed in full-
length toxin and distal from the rest of the toxin with a distance
between the C terminus of LLYlec and the N terminus of the
LLYCDC of about 34 A˚, a distance that could be straddled by
the missing 12-residue linker that joins the two. An alternative
model in which the lectin-binding site is buried would increase
the distance to about 44 A˚ but would require a much longer
linker to join the two ends and thus is not possible. A plausible
explanation for the observation of Farrand et al. is that it was their
N-terminal His tag (in particular, a highly charged acidic
sequence DDDDK associated with an enterokinase cleavage
site), rather than the rest of the toxin, that occluded the Lewis
antigen-binding site in the holotoxin.Structure 20, 24In healthy humans, Ley is expressed on cells in the upper
gastrointestinal tract (such as in the mouth and esophagus).
Because S. mitis normally colonizes the mouth, it is possible
that Ley expression is required for its establishment and/or
maintenance. Because Leb is more widespread, it suggests
that Ley is the primary ligand for initial infection and subsequent
cell lysis by the bacteria. Recently, LLY was shown to belong to
the CD59-binding family of CDCs, together with ILY and vagino-
lysin (Wickham et al., 2011). These CDCs use CD59, a GPI-
anchored protein, as a receptor on the surface of cells rather
than membrane cholesterol like the archetypical CDCs. It is
intriguing that CD59 has fucose linkages in the outer arms of
its N-linked glycan branches; hence, it is possible that the lectin
domain of LLY might bind to the N-linked glycan of CD59 as well
as through direct protein-protein interactions with domain 4 of
the toxin (Wickham et al., 2011). In any case, the presence of8–258, February 8, 2012 ª2012 Elsevier Ltd All rights reserved 255
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Lectinolysin-Lewis Antigen Complexesthe lectin domain in LLY suggests that its role is to enhance host
cell recognition by guiding the toxin to fucose-rich sites on the
surface of cells. In doing so, the toxin would concentrate at
such sites, thus promoting oligomerization and conversion into
the prepore state. It is possible that the specific location of the
fucose-binding site at one tip of the LLY molecule may act to
orient the toxin molecules with respect to each other and the
cell surface, thus enhancing head-to-head formation of produc-
tive oligomers.
Ley antigens are expressed at high levels in many cancers of
epithelial cell origin (e.g., colon, breast, lung, prostate, and ovary)
and, therefore, are a promising target for antibody-based immu-
notherapy (Yuriev et al., 2005). Thus, antibodies have been
sought that show a high degree of specificity for type 2 target
antigen while avoiding cross-reaction with type 1 antigens. The
conjugation of tumor-specific antibodies with cytotoxic mole-
cules has been shown to dramatically improve their clinical
utility. This has prompted one group recently to examine the
usefulness of conjugating a CDC, listeriolysin O, to a monoclonal
antibody that recognizes Lewis Y (Bergelt et al., 2009). Thus, it is
intriguing that nature has already engineered one suchmolecule,
LLY, to perform a similar job! The challenges ahead will be: to
understand the molecular basis by which the lectin domain
regulates LLY cytolytic activity and to explain why some
S. mitis strains produce this CDC and whether it contributes to
disease and/or the commensal state. Finally, we can engineer
the LLY lectin domain so that it specifically recognizes the Ley
antigen, which may be useful for the detection and/or targeting
of Ley-expressing tumor cells.EXPERIMENTAL PROCEDURES
Generation and Purification of LLYlec
A mutant of LLYlec (Q190C) with an amino-terminal 63His tag and a TEV
protease cleavage site for His tag removal was used in this study. The fusion
protein was expressed in E. coli BL21 (DE3) and purified as detailed in the
Supplemental Information. Purified LLYlec was concentrated to 10 mg/ml
and stored at 80C.Crystallization, Data Collection, and Structure Determination
We performed all crystallizations using the hanging drop vapor diffusion
method at 21C. Protein (2 ml) was mixed with equal volumes of protein and
hung over 1 ml of well solution. For data collection, all crystals were dipped
quickly and consecutively into 5% (vol/vol), 10% (vol/vol), and 15% (vol/vol)
glycerol in crystallization buffer. We collected data in house using an R-axis
IV imaging plate detector (Rigaku, Japan) with X-rays from a Micromax 007
X-ray generator (Rigaku, Japan), except for data from the apo LLYlec crystals,
which were collected at theMX1 beamline at the Australian Synchrotron (Clay-
ton, Victoria, Australia). Data collection was controlled with Blue-Ice software
(McPhillips et al., 2002). All data were processed with the HKL2000 suite (Ot-
winowski and Minor, 1997), and model building, including selection of water
molecules, was performed with COOT (Emsley and Cowtan, 2004). Data
were refined with REFMAC 5 (Murshudov et al., 1997) from the CCP4 program
suite [CCP4 (Collaborative Computational Project) Program Suite, 1994].
During refinement, we identified a putative Ni2+ ion that was covalently bound
to residue His 80 (Ni-N distance of 2.2 A˚) and coordinated to five water mole-
cules forming an octahedral geometry about the metal ion. We cannot rule out
that the ion may be Mg2+ because of the very high concentrations of this ion in
the crystallization buffer, even though this metal rarely forms covalent bonds
with nitrogen ligands. If Ni2+, the likely source of this ion was the Ni resin
used in the purification of LLYlec. Data statistics for all structures are listed in
Table 1.256 Structure 20, 248–258, February 8, 2012 ª2012 Elsevier Ltd All rWe set up crystallization trials of apo LLYlec using the protein crystallization
screen (Zeelen et al., 1994), with the protein at a concentration of 5 mg/ml. Bi-
pyramidial crystals appeared after 5 days in 2 M MgSO4 and 100 mM Tris
buffer, pH 8.5. After screening around this condition, the best crystals were ob-
tained in 2 M MgSO4 and 100 mM Tris buffer, pH 8.2 to 8.6, with maximal
dimensions of 0.15mm3 0.12 mm3 0.12mm. The crystals diffracted to reso-
lution of 1.9 A˚ in the tetragonal space group P43212. The structure was solved
with the program Phaser (Storoni et al., 2004; McCoy et al., 2007), with one
monomer of the fucose-binding module of the putative Streptococcus pneu-
moniae family 98 glycoside hydrolase (PDB code: 2J1R) used as a search
model. The sequence identity between the two domains is 47% (similarity of
67%). The results from Phaser gave a Z score of 27.3. One monomer was
found in the asymmetric unit and gave a Matthews coefficient (Matthews,
1968) of 3.30 Da/A˚3and a solvent content of 63%. After omitting a bound glyc-
erol molecule, we used the refined model as a starting model for determining
the initial phases for all the complexed carbohydrate structures.
Crystallization of the LLYlec-fucose complex was performed by incubating
the protein with 5 mM a-L-fucose (Sigma, Castle Hill, Australia) for 5 hr before
setting up the protein crystallization screen (Zeelen et al., 1994). Small crystals
were obtained under the same condition as the apo LLYlec crystals but took
14 days to grow instead of 5 days. These crystals exhibited the same shape
but were slightly smaller. The difference electron density maps for this
complex suggested that fucose was only partially occupied. An estimate of
its occupancy was made based on the disappearance of peaks/troughs in
difference Fourier maps and was supported by refined ligand B factors
being very similar to those of the surrounding side chains. To obtain crystals
of the LLYlec-Ley antigen complex, we soaked LLYlec crystals for 5 hr with
Ley antigen (Sigma) at a concentration of 5 mM. Similarly, the Leb antigen
complex was prepared by soaking apo LLYlec crystals in 5 mM Leb (Sigma)
overnight.
The Protein Interfaces, Surfaces and Assemblies server (http://www.ebi.ac.
uk/msd-srv/prot_int/pistart.html) was used for all protein-ligand surface inter-
action calculations.
SAXS
Hexahis _TEV_LLYT168C, a mutant of LLY, was expressed and purified for
SAXS analysis of full-length LLY (see Supplemental Information). We recorded
SAXS data on the SAXS/WAXS beamline at the Australian Synchrotron using
in-line gel filtration (Gunn et al., 2011). We performed ab initio shape recon-
structions using DAMMIF (Franke and Svergun, 2009). Averaged filtered shape
envelopes were generated from ensembles of DAMMIF envelopes with DAM-
AVER (Volkov and Svergun, 2003). We generated theoretical scattering
profiles from model coordinates and compared them to experimental data
using CRYSOL (Svergun et al., 1995), and the statistical analysis of goodness
of fit—Pc(c
2,n)—and the relative improvement between fits—PF(F,n1,n2)—
were performed as described by Mills et al. (2009). Rigid body refinement
was carried out with MASSHA (Konarev et al., 2001) and BUNCH (Petoukhov
and Svergun, 2005) to identify the likely position of the LLYlec domain. We per-
formed a more extensive search for alternative full-length models consistent
with the SAXS data using the ensemble optimized method (EOM) (Bernado´
et al., 2007).
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